Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation reports developments in structural heart medical technology, including surgical tissue valves, transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies. Company news commonly covers the SAPIEN TAVR platform, PASCAL transcatheter edge-to-edge repair technology, the EVOQUE transcatheter tricuspid valve replacement system, and RESILIA tissue used in surgical and transcatheter valve innovations.
Recurring updates include quarterly results, clinical-trial data presented at cardiovascular meetings, reimbursement and guideline developments affecting valve procedures, product pipeline commentary, healthcare conference appearances, access initiatives for structural heart treatment, and finance leadership or governance announcements.
BD (Becton, Dickinson and Company) has announced an agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition aims to expand BD's portfolio of smart connected care solutions and enhance its position in advanced monitoring technologies.
Critical Care, a global leader in advanced patient monitoring, generated over $900 million in revenue in 2023 and employs approximately 4,500 people. The acquisition is expected to be immediately accretive to BD's revenue growth, adjusted gross and operating margins, and adjusted earnings per share.
Critical Care will operate as a separate business unit within BD's Medical segment and will continue to be based in Irvine, California, under the leadership of Katie Szyman. The transaction is expected to close by the end of the calendar year, subject to regulatory reviews and closing conditions.
BD plans to fund the acquisition with a combination of $1 billion in cash and $3.2 billion in new debt. The company expects to achieve additional margin expansion and value through cost synergies and efficiencies.
Edwards Lifesciences has launched the SAPIEN 3 Ultra RESILIA valve in Europe, incorporating breakthrough RESILIA tissue technology for enhanced durability. The valve received CE Mark for patients with heart valve disease, with RESILIA tissue offering potential for extended durability. The valve aims to improve quality of life and future treatment options with lower rates of paravalvular leak and larger effective orifice areas. The technology is backed by 7-year COMMENCE Study data showing excellent outcomes. RESILIA tissue is a result of 20 years of research, indicating Edwards' focus on patient-centric technology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.